EWTX Stock Cash Flow Statements

Edgewise Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Edgewise Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

cash flows from operating activities
net income	-36,115,000	-40,798,000	-39,662,000	-34,129,000	-31,497,000	-28,525,000	-30,143,000	-25,713,000	-21,469,000	-22,838,000	-19,415,000	-17,498,000	-16,067,000	-14,660,000	-12,696,000	-12,949,000	-10,353,000	-6,815,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	523,000	513,000	577,000	539,000	480,000	473,000	483,000	449,000	424,000	195,000	88,000	100,000	97,000	83,000	78,000	64,000	51,000	79,000
stock-based compensation	7,733,000	9,059,000	7,737,000	6,880,000	5,224,000	4,871,000	5,153,000	4,559,000	4,011,000	3,837,000	3,736,000	3,173,000	2,037,000	1,978,000	1,873,000	1,548,000	687,000	296,000
accretion of discount on marketable securities	-2,203,000	-1,923,000
amortization of right-of-use asset	44,000	41,000	52,000	63,000	54,000	52,000	50,000	48,000	37,000	46,000	4,000	65,000	57,000	44,000
changes in assets and liabilities:
prepaid expenses and other assets	-2,472,000	-1,478,000	1,587,000	791,000	977,000	-63,000	-379,000	-1,157,000	-1,658,000	-359,000	279,000	-190,000	-1,939,000	398,000		1,060,000	-2,945,000	-66,000
accounts payable	-151,000	2,858,000	92,000	-1,028,000	1,893,000	780,000	-1,382,000	1,762,000	-312,000	-160,000	576,000	938,000	-2,655,000	1,188,000	1,551,000	-524,000	1,690,000	-63,000
accrued compensation	1,661,000	-6,081,000	3,870,000	1,942,000	1,319,000	-2,770,000	1,287,000	1,283,000	1,051,000	-1,958,000	1,328,000	680,000	678,000	-1,451,000	767,000	657,000	701,000	-503,000
accrued other incomes and other liabilities	-1,415,000	122,000	1,098,000	987,000	-825,000	-102,000	390,000	-811,000	577,000	370,000
lease liability	-187,000	-179,000	294,000	-179,000	-171,000	-164,000	-117,000	-103,000	0	116,000	1,812,000	1,041,000	43,000	24,000
net cash from operating activities	-32,582,000	-37,866,000	-26,957,000	-27,374,000	-26,099,000	-28,598,000	-26,830,000	-22,058,000	-20,234,000	-22,826,000	-11,820,000	-11,998,000	-16,245,000	-12,572,000	-9,419,000	-8,262,000	-9,769,000	-6,057,000
capex	-50,000	-44,000	-274,000	-520,000	-221,000	-297,000	-161,000	-457,000	-759,000	-4,368,000	-3,293,000	-1,330,000	-554,000	-369,000	-79,000	-451,000	-76,000	-62,000
free cash flows	-32,632,000	-37,910,000	-27,231,000	-27,894,000	-26,320,000	-28,895,000	-26,991,000	-22,515,000	-20,993,000	-27,194,000	-15,113,000	-13,328,000	-16,799,000	-12,941,000	-9,498,000	-8,713,000	-9,845,000	-6,119,000

cash flows from investing activities
purchases of marketable securities	-263,762,000	-122,180,000	-63,178,000	-45,319,000	-40,955,000	-327,603,000	-39,786,000	-84,667,000	-114,455,000	-16,958,000	-146,691,000	-67,990,000	-63,751,000	-13,956,000	-15,044,000	-41,357,000	-167,091,000	-64,711,000
sales of marketable securities	23,650,000	15,000,000	3,074,000	10,961,000	874,000	885,000	929,000	14,043,000	4,539,000	607,000	4,529,000	12,719,000	4,494,000	8,832,000
maturities of marketable securities	77,996,000	151,122,000	81,300,000	60,240,000	77,670,000	58,707,000	66,001,000	94,500,000	114,117,000	69,761,000	69,859,000	30,280,000	59,765,000	36,879,000	25,800,000	10,200,000
purchases of property and equipment	-50,000	-44,000	-274,000	-520,000	-221,000	-297,000	-161,000	-457,000	-759,000	-4,368,000	-3,293,000	-1,330,000	-554,000	-369,000	-79,000	-451,000	-76,000	-62,000
net cash from investing activities	-162,166,000	43,898,000	20,922,000	25,362,000	37,368,000	-268,308,000	26,983,000	23,419,000	3,442,000	49,042,000	-75,596,000	-26,321,000	-46,000	31,386,000	14,121,000	-31,608,000	-159,967,000	-64,773,000
cash flows from financing activities
proceeds from issuance of common stock, net of offering costs
exercise of stock options	233,000	2,261,000	2,430,000	3,547,000	1,577,000	1,926,000	62,000	3,000	31,000	21,000	25,000	52,000	255,000	73,000	45,000	37,000	7,000	23,000
payment of deferred offering costs		-38,000	0	-214,000
proceeds from employee stock purchase plan			465,000	0			258,000	0			142,000	0
net cash from financing activities	188,231,000	2,223,000	2,895,000	3,333,000	1,952,000	241,073,000	52,987,000	-211,000	369,000	21,000	-338,000	129,725,000	179,000	73,000	293,000	37,000	-896,000	186,950,000
net change in cash and cash equivalents	-6,517,000	8,255,000	-3,140,000	1,321,000	13,221,000	-55,833,000	53,140,000	1,150,000	-16,423,000	26,237,000	-87,754,000	91,406,000	-16,112,000	18,887,000	4,995,000	-39,833,000	-170,632,000	116,120,000
cash and cash equivalents at beginning of period	0	41,666,000	0	0	0	86,097,000	0	0	0	21,993,000	0	0	0	15,566,000	0	0	0	104,916,000
cash and cash equivalents at end of period	-6,517,000	49,921,000	-3,140,000	1,321,000	13,221,000	30,264,000	53,140,000	1,150,000	-16,423,000	48,230,000	-87,754,000	91,406,000	-16,112,000	34,453,000	4,995,000	-39,833,000	-170,632,000	221,036,000
supplemental disclosures of non-cash investing and financing activities:
property and equipment purchases included in accounts payable													142,000	309,000
deferred offering costs included in accounts payable and accrued other incomes		395,000
proceeds from issuance of common stock, net of underwriting discounts and commissions and offering costs			0	0	0	239,147,000
property and equipment purchases included in accounts payable and accrued other incomes			-160,000	88,000	-28,000	144,000	87,000	-184,000	124,000	200,000	-70,000
right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable							0	-8,000	0	1,118,000		-184,000	-502,000	2,174,000
amortization (accretion) of (discount) on marketable securities				-3,240,000
reduction to right-of-use due to tenant improvement receivable
amortization (accretion) of premium (discount) on marketable securities						-3,150,000	-2,172,000	-2,375,000	-2,895,000	-2,075,000	-1,755,000	127,000	415,000	670,000
proceeds from issuance of common stock, net of underwriting discounts and commissions
payment of offering costs and deferred offering costs
offering costs and deferred offering costs included in accounts payable and accrued other incomes
deferred offering costs included in accrued expenses														141,000
proceeds from initial public offering of common stock, net of underwriting discounts and commissions and offering costs															0	0	-903,000	187,051,000
payment of preferred stock issuance costs															0	0	0	-124,000
right-of-use asset obtained in exchange for new operating lease liability, net of reimbursed tenant improvements
conversion of convertible preferred stock upon closing of initial public offering															0	0	0	160,214,000
accrued other incomes												-434,000	1,089,000	-846,000	-551,000	1,882,000	400,000	1,015,000
debt proceeds
property and equipment purchases included in debt
receivable for option exercises																		2,000
unpaid initial public offering costs included in accounts payable																		495,000
unpaid initial public offering costs included in accrued expenses																		408,000
prepaid expenses, other assets and other long-term liabilities
proceeds from issuance of series b-2 convertible preferred stock
proceeds from issuance of series c convertible preferred stock
supplemental disclosures of non-cash financing activities:
preferred stock issuance costs included in accrued other incomes

We provide you with 20 years of cash flow statements for Edgewise Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Edgewise Therapeutics stock. Explore the full financial landscape of Edgewise Therapeutics stock with our expertly curated income statements.

The information provided in this report about Edgewise Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.